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Abstract
Introduction—Extremely low gestational age newborns (ELGANs) are at increased risk of chronic
lung disease (CLD) and of developmental delay. Some studies have suggested that CLD contributes
to developmental delay.
Patients and Methods—We examined data collected prospectively on 915 infants born before
the 28th week of gestation in 2002–2004 who were assessed at 24 months of age with the Bayley
Scales of Infant Development-2nd Edition or the Vineland Adaptive Behavior Scales. We excluded
infants who were not able to walk independently (Gross Motor Function Classification System score
< 1) and, therefore, more likely to have functionally important fine motor impairments. We defined
CLD as receipt of oxygen at 36 weeks' postmenstrual age and classified infants as either not receiving
mechanical ventilation (MV) (CLD without MV) or receiving MV (CLD with MV).
Results—Forty-nine percent of ELGANs had CLD; of these, 14% were receiving MV at 36 weeks'
postmenstrual age. ELGANs without CLD had the lowest risk of a Mental Developmental Index
(MDI) or a Psychomotor Developmental Index (PDI) of <55, followed by ELGANs with CLD not
receiving MV, and ELGANs with CLD receiving MV (9%, 12%, and 18% for the MDI and 7%,
10%, and 20% for the PDI, respectively). In time-oriented multivariate models, the risk of an MDI
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of <55 was associated with the following variables: gestational age of <25 weeks; single mother; late
bacteremia; pneumothorax; and necrotizing enterocolitis. The risk of a PDI of <55 was associated
with variables such as single mother, a complete course of antenatal corticosteroids, early and
persistent pulmonary dysfunction, pulmonary deterioration during the second postnatal week,
pneumothorax, and pulmonary interstitial emphysema. CLD, without or with MV, was not associated
with the risk of either a low MDI or a low PDI. However, CLD with MV approached, but did not
achieve, nominal statistical significance (odds ratio: 1.9 [95% confidence interval: 0.97–3.9]) for the
association with a PDI of <55.
Conclusions—Among children without severe gross motor delays, risk factors for CLD account
for the association between CLD and developmental delay. Once those factors are considered in
time-oriented risk models, CLD does not seem to increase the risk of either a low MDI or a low PDI.
However, severe CLD might increase the risk of a low PDI.
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Chronic lung disease (CLD) (also known as bronchopulmonary dysplasia) seems to place an
infant at increased risk of early developmental delays,1–3 cognitive impairment,4–6 language
impairment,7,8 and poor academic performance.9 Predictors and correlates of CLD, such as
prolonged mechanical ventilation (MV), are also associated with an increased risk of cognitive
impairment.10–12
CLD is associated with global dysfunction rather than specific neuropsychological
impairments.13 The more severe the CLD, the greater the probability of developmental
impairment.14–16 The putative causal pathways from antenatal events to the development of
CLD involve multiple antecedents, effect modifiers, and confounders (chorioamnionitis,
preterm birth, antenatal steroids, postnatal infection, patent ductus arteriosus [PDA], and fluid
management, etc).17,18
Although 2 randomized, controlled, clinical trials have shown that medications that reduce the
risk of CLD also reduce the risk of neurodevelopmental impairment (eg, caffeine19,20 and
vitamin A21,22), the underlying mechanisms have not been identified.23 Thus, we still do not
know to what extent CLD, its antecedents, or comorbid conditions contribute to
neurodevelopmental impairment.
The Extremely Low Gestational Age Newborn (ELGAN) study assessed measures of
pulmonary dysfunction as well as prenatal, antenatal, and postnatal exposures and events.24,
25 The purpose of the analyses presented here was to explore to what extent CLD and its
antecedents influence the risk of developmental delays at 24-months adjusted age, as assessed
with the Bayley Scales of Infant Development-2nd Edition (BSID-II),26 among infants without
gross motor function impairments.
Patients and Methods
The ELGAN Study
The ELGAN study identified characteristics and exposures that increase the risk of structural
and functional neurologic disorders in ELGANs. During the years 2002-2004, women
delivering before 28 weeks' gestation at 1 of 14 participating institutions were asked to enroll
in the study. The enrollment and consent processes were approved by the individual
institutional review boards. We limited the sample to children who were assessed at 24 months
of age with the BSID-II or the Vineland Adaptive Behavior Scales (VABS). Fine motor
impairments, which interfere with the Mental developmental index (MDI) and the
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Psychomotor developmental index (PDI) assessments, tend to accompany gross motor
dysfunctions. To avoid attributing cognition and perception deficits to motor impairments, we
limited our analyses to children who were able to walk independently (Gross Motor Function
Classification System [GMFCS] < 1), and who, therefore, were unlikely to have functionally
important fine motor impairments.
Demographic, Pregnancy, and Newborn Variables
The clinical circumstances that led to each maternal admission and ultimately to each preterm
delivery were defined a priori.27 The gestational age estimates were based on a hierarchy of
the quality of available information.24,25 The birth weight z score is the number of SDs the
infant's birth weight is above or below the median weight of infants at the same gestational age
in a standard data set.28 We collected the physiology, laboratory, and therapy data for the first
12 hours needed to calculate a Score for Neonatal Acute Physiology-II (SNAP-II).29
During the first week, details about the newborn were collected daily, then weekly thereafter
through the first month (days 7, 14, 21, and 28). Infants were classified by their respiratory
characteristics during the first 2 postnatal weeks as “persistently low fraction of inspired
oxygen [FIO2]” (FIO2 consistently below 0.23 on all days between days 3 and 7 and FIO2 ≤ 0.25
on day 14), “pulmonary deterioration” (PD) (FIO2 < 0.23 on any day between days 3 and 7 and
FIO2 > 0.25 on day 14), and “early and persistent pulmonary dysfunction” (EPPD) (FIO2 > 0.23
on all days between days 3 and 7 and FIO2 > 0.25 on day 14).24 Late bacteremia was defined
as recovery of an organism from blood drawn during postnatal weeks 2, 3, or 4.
Pneumothorax, pulmonary interstitial emphysema (PIE), pulmonary hemorrhage, and PDA
(clinical and echocardiographic) were recorded. Ophthalmologists examined the eyes of the
infants according to protocol and completed forms specifically for the ELGAN study.
Definitions of retinopathy of prematurity (ROP) were those definitions endorsed by the
International Committee for Classification of Retinopathy of Prematurity.30
The diagnosis of CLD was made at 36 weeks' postmenstrual age (PMA). If an infant was
receiving supplemental oxygen, the infant was classified as having CLD, and further classified
on the level of respiratory support: CLD with MV (either conventional MV [CMV] or high-
frequency ventilation) or CLD without MV. Necrotizing enterocolitis (NEC) was classified
according to the modified Bell staging system.31
Protocol Ultrasound Scans
Cranial ultrasound scans were performed by technicians at all of the hospitals by using digitized
high-frequency transducers (7.5 and 10 MHz) and included the standard views.32 The 3 sets
of protocol scans were defined by the postnatal day on which they were obtained (days 1–4,
5–14, and ≥15). Reading procedures and efforts to reduce observer variability are presented
elsewhere.33
24-Month Developmental Assessment
The assessment at 24-months' corrected age included the BSID-II,26 a neurologic examination,
34 an assessment of gross motor function by using the GMFCS35 and, when necessary, a parent-
reported assessment of adaptive development by using the VABS.36 Seventy-seven percent of
the children had developmental assessments within the range of 23.5 to 27.9 months; of the
other children, about half were assessed before 23.5 months and about half after 27.9 months.
Certified examiners administered and scored the BSID-II. All examiners had previous
experience with the BSID-II and attended a 1-day workshop at which the published guidelines
for test administration and videotaped examinations were viewed and discussed. Examiners
Laughon et al. Page 3













were aware of the infant's enrollment in the ELGAN study but were not informed of any
specifics of the child's medical history. Examiners were told the child's corrected age.
As suggested by the test manual, we defined a significant delay for the BSID-II Mental and
Motor scales as a score <70, a score that is more than 2 SDs below the mean for the
standardization sample. We also evaluated associations with MDIs and PDIs of <55, which
are more than 3 SDs below the mean for the standardization sample. When a child's
impairments precluded administration of the BSID-II, or >2 items were omitted or judged to
be “unscoreable,”the child was classified as nontestable on that scale. The Adaptive Behavioral
Composite of the VABS was obtained for 26 of 33 children who were considered nontestable
with the BSID-II Mental scale. For these infants, the Adaptive Behavioral Composite was used
as an approximation of the MDI. Among infants unscoreable with the BSID-II Motor scale,
32 were assessed in the Motor Skills Domain of the VABS and that score was used as an
approximation of the PDI.
Data Analysis
Data analysis was oriented to test the hypothesis that antecedents of CLD, and not CLD itself,
contribute to suboptimal performance on the BSID-II. We assessed associations between
antecedents (antenatal and postnatal variables and CLD) and low MDIs and PDIs.
Relationships were assessed with Pearson's χ2, and variables associated with both CLD and a
low BSID-II at a P value of ≤.30 were considered candidates for logistic regression analyses.
37
Because postnatal phenomena, such as the need for ventilation, can be influenced by
antepartum phenomena, we created logistic regression models in which risk factors were
ordered in a temporal pattern, so that the earliest occurring predictors/covariates of an outcome
(eg, MDI < 55) were entered first and were not displaced by later occurring covariates.11,38–
42 For these time-oriented risk models (TORMs), we categorized sets of antecedents/covariates
by the time they occurred or were identified. Each set is called an epoch. We used a step down
procedure seeking a parsimonious solution without interaction terms. To account for the
possibility that infants born at a particular hospital are more like each other than like infants
born at other hospitals, a hospital cluster term was included in all models.43
Results
The cohort comprised 915 children whose CLD status at 36 weeks was known and were able
to walk independently (GMFCS < 1) at the 24-month follow-up assessment (Fig 1). Ninety-
six infants had a GMFCS ≥1 and were excluded. The 450 children who were treated with
oxygen at 36 weeks' PMA (ie, had CLD) were more likely than their 465 peers who were not
oxygen dependent to have an MDI in the severely delayed range (<55:13% vs 9%), although
the 2 groups did not differ in the percentage of infants in the less severely delayed range (55–
69: 10% vs 11%) (Table 1). MDIs in the 55 to 69 range tended to be modestly overrepresented
among infants who had CLD with MV (15% vs 10% in the CLD without MV group versus
11% in the no CLD group). MDIs of <55 were more prominently overrepresented among
children who had CLD with MV (18% vs 12% in the CLD without MV group versus 9% in
the no CLD group).
Univariate Associations With CLD and BSID-II Scores
We chose to compare children with CLD to those children with no CLD without additional
classification into CLD with or without MV because only 65 children were receiving MV at
36 weeks' PMA. A number of associations were observed for an increased risk of CLD and an
increased risk of both an MDI and a PDI of <55, including lower birth weight z scores, higher
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SNAP-IIs, and lower Pao2 values (lowest quartiles) at the end of each of the first 2 weeks
(Table 2). Children who had late bacteremia were at an increased risk of CLD, an MDI of <55,
and a PDI between 55 and 69. Placental abruption was not associated with CLD, but was
associated with a lower risk of an MDI and a PDI of <55.
Aggressive modes of ventilation on days 7, 14, 21, and 28 were associated with a greater risk
of CLD, as well as a greater risk of an MDI of <55and a PDI of <55 (Table 3). Treatment at
36 weeks' PMA with any form of respiratory support (continuous positive airway pressure
[CPAP], CMV, or high-frequency ventilation) was associated with an increased risk of an MDI
and a PDI of <55.
Receipt of a methylxanthine for more than 2 weeks was associated with a reduced risk of CLD,
an MDI of <55, and a PDI of 55 to 69 (Table 4). Conversely, an increased risk of CLD and an
increased risk of MDI and a PDI <55 were associated with receipt of hydrocortisone and with
PDA ligation. Children who received an analgesic, a sedative, or multiple transfusions of
packed red blood cells were at higher risk than others of CLD and a low MDI. Treatment with
dexamethasone was associated with an increased risk of CLD, an MDI of <70, and a PDI of
<70.
Pneumothorax, PIE, PD, EPPD, and higher stages of NEC and ROP were associated with an
increased risk of CLD and a low MDI and a low PDI (Table 5). The diagnosis of PDA was
associated with an increased risk of CLD, but not a low MDI or a low PDI. Ventriculomegaly
and an echolucent lesion were not associated with an increased risk for CLD, but were
minimally associated with a low MDI, and modestly with a low PDI.
Time-Oriented Risk Models
Because the associations between CLD categories (no CLD, CLD without MV, and CLD with
MV) with both the MDI and the PDI were most evident for scores <55, we limited our models
to these outcomes. We created 3 epoch models of the MDI and the PDI at <55. We grouped
prenatal and birth characteristics and exposures into the antenatal epoch, all exposures and
characteristics during the first 28 days into the neonatal epoch, and exposures and
characteristics occurring or reported between 28 days and 36 weeks' PMA into the 36-weeks'
PMA epoch.
In the antenatal epoch of the TORM for an MDI of <55, gestational age of 23 or 24 weeks,
single mother, and the composite variable “preeclampsia or fetal indication” were associated
with an increased risk of an MDI of <55 (Table 6). In the neonatal epoch, late bacteremia,
pneumothorax, and NEC of Bell stage II or higher were also associated with an MDI of <55.
Neither CLD without MV nor CLD with MV, added in the last epoch, achieved statistical
significance for an MDI of <55 after we accounted for the antenatal and neonatal epoch
variables.
In the antenatal epoch of the TORM for a PDI <55, single mother, a complete course of
antenatal steroids, and the composite variable “preeclampsia or fetal indication” were
associated with an increased risk of a PDI <55 (Table 7). In the neonatal epoch, pneumothorax,
PIE, PD, and EPPD were also associated with a PDI <55. Neither CLD without MV nor CLD
with MV achieved statistical significance for a PDI <55 after we accounted for the antenatal
and neonatal epoch variables. However, CLD with MV approached, but did not achieve,
nominal statistical significance (odds ratio [OR]: 1.9 [95% confidence interval (CI): 0.97–3.9])
for the association with a PDI <55.
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After adjusting for confounders and other antecedents, we found that CLD, even when adjusted
for severity, was not associated with an increased risk of delayed development at 24-months
adjusted age. On the other hand, antecedents of CLD seemed to be associated with impaired
development. Several potential reasons might explain our observations: (1) brain injury occurs
as a consequence of antecedents of CLD (eg, infection, pneumothorax, respiratory, and other
therapies), rather than CLD itself; (2) brain injury is caused by CLD; however, this association
was masked in the multivariate model by previous adjustment for factors in the causal chain
leading to CLD; or (3) lung dysfunctions, and associated therapies, are indicators of maturation-
associated vulnerabilities of lung and brain.
In reports of developmental delay identified with the BSID-II, study participants are often
classified by whether their scores are <70, which according to the test developers indicates
“significantly delayed performance.”26 However, studies of extremely low birth weight infants
indicate that an appreciable proportion of infants with an MDI of <70 do not have mental
retardation when assessed at school age.44,45 By dichotomizing BSID-II scores at 55, we
increased the positive predictive value of the definition of developmental delay used in this
study. We also restricted our analyses to children who were free from moderate or severe gross,
and presumably fine, motor function impairments, which were almost always because of
cerebral palsy. The present study estimates the strength of association between CLD and
developmental delay at 24 adjusted months only in children who do not have cerebral palsy.
Significant fine motor impairment precludes valid assessment of cognitive functioning with
the MDI portion of the BSID-II.
However, cerebral palsy is associated with mental retardation.46 If CLD contributes causally
to the outcome of cerebral palsy with mental retardation, then our exclusion of infants with
cerebral palsy results in an understatement of the strength of the CLD/MDI < 55 relationship.
On the other hand, this sample restriction provides a more informative analysis of the
relationship of CLD to delayed cognitive and perceptual motor development.
Previous studies attribute much of the increased risk of delayed development to antecedents
of CLD. For example, late bacteremia might prolong the need for MV, and prolonged MV is
associated with developmental delay.47 In another example, prolonged ventilation and
hypocarbia, antecedents of CLD, are associated with ultrasonographically detectable cerebral
white matter damage,48 which is, in turn, associated with developmental delay.49,50 We also
found that a number of our variables were highly correlated. For example, EPPD and PD predict
a low PDI. It is possible that each of these variables conveys information about immaturity of
the brain as well as the lung, along with information about exposures that might be in the causal
chain leading to a low PDI. Our analyses suggest that it is not CLD, but rather risk factors for
CLD, that are more closely linked to developmental delay at 24-months adjusted age. Once
these risk factors are considered, CLD imparts no significant additional risk.
Traditionally, risk factors for both a low MDI and a low PDI have been considered together.
In the analyses presented here, a low MDI and a low PDI shared antecedents, but some risk
factors were antecedents of one but not of the other. This observation suggests that the
pathogenesis of developmental delay differs for mental and motor domains.50 Both late
bacteremia51 and higher grade NEC52,53 have been identified as antecedents of a low MDI.
What they have in common is a systemic inflammatory response that might lead to cerebral
white matter injury,54 which predicts low MDI and low PDI scores.50 An inflammatory
response, initiated in the intestinal compartment, may become systemic and lead to brain injury
through a variety of inflammatory mediators such as tumor necrosis factor α, interleukin 6, and
platelet activating factor.55,56 Interventions that have been associated with a lower risk of NEC,
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such as probiotics57 and human milk feeding58 might improve developmental outcome, as
observed in recent studies of human milk and developmental outcome.59
Low PDI seems to be related to factors associated with pulmonary disease (eg, pneumothorax,
PIE, PD, and EPPD). Two previous studies15,60 found that the association of CLD and
developmental delay arises primarily from the group of infants with severe CLD. Pulmonary
inflammation, either initiated or exacerbated by oxygen toxicity and injury from MV, plays a
major role in the pathogenesis of CLD. Although lung inflammation may be confined within
the lungs, under certain conditions, it may also be accompanied by a systemic inflammatory
response.61 It is possible that a systemic inflammatory response associated with prolonged MV
(ie, among infants with CLD with MV) might increase the likelihood of neonatal brain injury
and subsequent disability. Our inability to demonstrate this relationship conclusively may have
resulted from the relatively small number of infants with CLD with MV in our sample.
Alternatively, the need for ventilator assistance and/or ventilator-associated lung injuries might
be markers for immaturity-related brain vulnerability, and might not be causally related. It is
also possible that by excluding infants with significantly impaired gross motor function, we
may have understated the strength of association between severe CLD and development delay.
Compared with the infants of married mothers, infants of single mothers were at higher risk
for delayed cognitive development. “Single mother” may be a variable that summarizes
disadvantaged social class correlates. Social disadvantage has repeatedly been found as a
predictor of impaired development in children born preterm.1–3,62–64 Explanations include
potential contributions of genetics and limited access to resources that enhance development.
Delayed development was more frequent among children whose mothers were treated with
antenatal steroids than among children not exposed in utero to exogenous steroids. An
explanation for the apparent adverse effect of antenatal steroids is that antenatal steroids were
not randomly assigned, so confounding by indication is likely to have occurred.65 For example,
deliveries in response to maternal and fetal indication tend to have higher rates of antenatal
steroids than “spontaneous” deliveries. Another explanation is that exposure to antenatal
steroids might have improved survival, which may come at the expense of greater risk of
impairment.66
Our study offers several advantages over previous studies. First, we selected infants on the
basis of gestational age, not birth weight, to minimize confounding because of factors related
to fetal growth restriction.67 Second, examiners were not aware of the medical histories of the
children they examined, thereby minimizing “diagnostic suspicion bias.”68 Third, high quality
ultrasonographic data describing brain damage were available to us as a result of rigorous
efforts to minimize variability in sonologists' interpretations.33
Conclusions
Antecedents and correlates of CLD are associated strongly with the risk of delayed mental and
motor development. Infants with CLD who were receiving MV at 36 weeks' adjusted age might
have an increased risk of neurodevelopmental impairment. This observation will inform future
investigations of the biological mechanisms underlying the association between CLD and later
neurodevelopmental impairments affecting former preterm infants.
• What's Known on This Subject: Some studies suggest that CLD in ELGANs is
associated with neurodevelopmental impairments.
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• What This Study Adds: Among children without severe gross motor delays, risk
factors for CLD account for the association between CLD and developmental
delay. However, severe CLD might increase the risk of lower motor scores.
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CLD chronic lung disease
MV mechanical ventilation
PDA patent ductus arteriosus
ELGAN extremely low gestational age newborn
BSID-II Bayley Scales of Infant Development-2nd Edition
VABS Vineland Adaptive Behavioral Scales
MDI Mental developmental index
PDI Psychomotor developmental index
GMFCS Gross Motor Function Classification System
SNAP-II Score for Neonatal Acute Physiology-II
FIO2 fraction of inspired oxygen
PD pulmonary deterioration
EPPD early and persistent pulmonary dysfunction
PIE pulmonary interstitial emphysema
ROP retinopathy of prematurity
PMA postmenstrual age
CMV conventional mechanical ventilation
NEC necrotizing enterocolitis
TORM time-oriented risk model
CPAP continuous positive airway pressure
OR odds ratio
CI confidence interval
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TABLE 6
ORs and 95% CIs Obtained With TORMs of MDI <55
Epoch Epoch, OR (95% CI)
Antenatal Neonatal (First 28 d) 36 wk PMA
Antenatal
 Gestational age 23–24 wk 1.7 (1.00–3.1) 1.4 (0.6–3.0) 1.3 (0.7–2.8)
 Single mother 2.3 (1.5–3.5) 2.3 (1.5–3.5) 2.3 (1.5–3.6)
 Preeclampsia or fetal
indication
2.0 (1.01–3.8) 1.9 (0.96–3.8) 1.9 (0.9–3.8)
Neonatal (first 28 d)
 Late bacteremia — 1.8 (1.3–2.5) 1.8 (1.3–2.5)
 Pneumothorax — 3.7 (2.6–5.4) 3.6 (2.5–5.4)
 NEC ≥ stage II — 2.2 (1.3–3.7) 2.1 (1.2–3.7)
36 wk PMA
 CLD without MV — — 1.1 (0.8–1.4)
 CLD with MV — — 1.2 (0.7–2.3)
These analyses include only those children without a severe gross motor impairment (GMFCS score < 1). Antenatal epoch includes the following
variables: gestational age of 23–24 weeks; gestational age of 25–26 weeks; single mother; complete course of antenatal steroids; cesarean delivery;
and delivery for preeclampsia or fetal indications. Neonatal epoch includes the following variables: SNAP-II in the top quartile; MV or high-frequency
ventilation at 7 days; late bacteremia; pneumothorax; PIE; Pao2 in the lowest quartile (week 1); Pao2 missing (week 1); transfusions (packed red
blood cells); PD; EPPD; ventriculomegaly; echolucent lesion; echodense lesion; NEC stage II or worse; methylxanthine; PDA; and PDA ligation.
Thirty-six weeks' PMA epoch includes the following variables: CLD without MV (CMV or high-frequency ventilation) at 36 weeks and CLD with
MV.
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TABLE 7
ORs and 95% CIs Obtained With TORMs of PDI <55
Epoch Epoch, OR (95% CI)




 Single mother 1.8 (1.02–3.0) 1.8 (0.95–3.5) 1.8 (0.9–3.5)
 Complete antenatal corticosteroids 2.3 (1.5–3.5) 2.4 (1.5–3.9) 2.4 (1.5–3.8)
 Preeclampsia or fetal indication 2.2 (1.5–3.1) 2.3 (1.7–3.3) 2.2 (1.5–3.2)
Neonatal (first 28 d)
 Pneumothorax — 1.9 (1.1–3.5) 1.9 (1.1–3.3)
 PIE — 2.2 (1.04–4.7) 2.0 (0.99–4.2)
 PD — 3.6 (1.2–7.6) 2.7 (1.1–6.5)
 EPPD — 3.0 (1.2–7.6) 2.7 (1.1–6.5)
36 wk PMA
 CLD without MV — — 1.1 (0.6–2.0)
 CLD with MV — — 1.9 (0.97–3.9)
These analyses include only those children without a severe gross motor impairment (GMFCS score < 1). Antenatal epoch includes the following
variables: gestational age of 23–24 weeks; gestational age of 25–26 weeks; single mother; complete course of antenatal corticosteroids; cesarean
delivery; and delivery for preeclampsia or fetal indications. Neonatal epoch includes the following variables: SNAP-II in the top quartile; MV or high-
frequency ventilation at 7 days; late bacteremia; pneumothorax; PIE; Pao2 in the lowest quartile (week 1); Pao2 missing (week 1); transfusions (packed
red blood cells); PD; EPPD; ventriculomegaly; echolucent lesion; echodense lesion; NEC stage II or worse; methylxanthine; PDA; and PDA ligation.
Thirty-six weeks' PMA epoch includes the following variables: CLD without MV (CMV or high-frequency ventilation) at 36 weeks and CLD with
MV.
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